Clinical Studies In Japan Today: Another Look At The World’s Second-Largest Prescription Drug Market In A Post-Pandemic World

The Latest Insights into Clinical Studies in Japan

The Pharma industry has compelling reasons to include Japan in clinical trials and the country’s response to the COVID-19 pandemic has only furthered the country’s appeal to the rest of the pharma industry.

Access this free thought leadership article from Japan’s largest CRO, CMIC, in association with Scrip for all the latest insights.

Key takeaways include:

• Recent efforts to reduce regulatory issues in Japan
• The challenges and developments in patient recruitment and engagement
• Considerations for site selection and site management
• Customizing decentralized clinical trials and the future of hybrid trials in Japan